 Scott Demarest
Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spasms, Infantile | 29 | 2024 | 104 | 10.870 |
Why?
| | Epileptic Syndromes | 23 | 2024 | 63 | 8.770 |
Why?
| | Epilepsy | 19 | 2023 | 290 | 6.000 |
Why?
| | Precision Medicine | 5 | 2022 | 363 | 1.950 |
Why?
| | Vision Disorders | 6 | 2023 | 135 | 1.680 |
Why?
| | Anticonvulsants | 9 | 2023 | 184 | 1.670 |
Why?
| | Genetic Testing | 5 | 2023 | 389 | 1.600 |
Why?
| | Seizures | 13 | 2023 | 345 | 1.470 |
Why?
| | Gene Editing | 2 | 2021 | 63 | 1.430 |
Why?
| | Pregnanolone | 2 | 2023 | 21 | 1.170 |
Why?
| | Epilepsies, Myoclonic | 3 | 2020 | 42 | 0.980 |
Why?
| | Epilepsy, Tonic-Clonic | 1 | 2023 | 4 | 0.970 |
Why?
| | Genetic Therapy | 2 | 2021 | 267 | 0.900 |
Why?
| | Disorders of Excessive Somnolence | 1 | 2022 | 26 | 0.850 |
Why?
| | Long QT Syndrome | 1 | 2022 | 57 | 0.830 |
Why?
| | Gain of Function Mutation | 1 | 2021 | 30 | 0.820 |
Why?
| | Haploinsufficiency | 1 | 2021 | 47 | 0.810 |
Why?
| | Neurodevelopmental Disorders | 2 | 2021 | 116 | 0.760 |
Why?
| | Child | 25 | 2024 | 19129 | 0.740 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2022 | 117 | 0.740 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 245 | 0.740 |
Why?
| | Child, Preschool | 15 | 2024 | 9491 | 0.690 |
Why?
| | Infant | 16 | 2024 | 8293 | 0.670 |
Why?
| | Sleep Wake Disorders | 1 | 2022 | 240 | 0.660 |
Why?
| | Brain Waves | 1 | 2018 | 22 | 0.660 |
Why?
| | Electroencephalography | 9 | 2023 | 387 | 0.650 |
Why?
| | Symptom Assessment | 1 | 2019 | 123 | 0.630 |
Why?
| | Developmental Disabilities | 2 | 2019 | 247 | 0.600 |
Why?
| | Humans | 47 | 2024 | 118959 | 0.560 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 453 | 0.540 |
Why?
| | MELAS Syndrome | 1 | 2014 | 3 | 0.510 |
Why?
| | Genetic Predisposition to Disease | 1 | 2023 | 2275 | 0.490 |
Why?
| | Genetic Association Studies | 3 | 2020 | 371 | 0.460 |
Why?
| | DNA, Mitochondrial | 1 | 2014 | 187 | 0.450 |
Why?
| | Quality of Life | 6 | 2023 | 2363 | 0.450 |
Why?
| | Movement Disorders | 3 | 2023 | 45 | 0.440 |
Why?
| | Clinical Trials as Topic | 3 | 2021 | 969 | 0.410 |
Why?
| | Adolescent | 11 | 2024 | 18480 | 0.400 |
Why?
| | Adrenocorticotropic Hormone | 3 | 2023 | 152 | 0.400 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2674 | 0.390 |
Why?
| | Double-Blind Method | 3 | 2023 | 1687 | 0.380 |
Why?
| | Cohort Studies | 5 | 2021 | 5116 | 0.360 |
Why?
| | Lennox Gastaut Syndrome | 2 | 2021 | 16 | 0.360 |
Why?
| | Rett Syndrome | 3 | 2024 | 23 | 0.340 |
Why?
| | Surveys and Questionnaires | 6 | 2023 | 4707 | 0.340 |
Why?
| | Male | 19 | 2023 | 57795 | 0.330 |
Why?
| | Female | 19 | 2023 | 61559 | 0.310 |
Why?
| | Mutation | 5 | 2021 | 3457 | 0.300 |
Why?
| | Treatment Outcome | 6 | 2023 | 9341 | 0.290 |
Why?
| | Brain | 2 | 2014 | 2489 | 0.270 |
Why?
| | Phenotype | 5 | 2021 | 3003 | 0.260 |
Why?
| | Status Epilepticus | 1 | 2023 | 36 | 0.230 |
Why?
| | Young Adult | 5 | 2024 | 10793 | 0.230 |
Why?
| | Sex Factors | 2 | 2019 | 1781 | 0.220 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2023 | 111 | 0.220 |
Why?
| | Adult | 8 | 2024 | 31510 | 0.220 |
Why?
| | Vigabatrin | 2 | 2023 | 18 | 0.210 |
Why?
| | Brain Diseases | 1 | 2023 | 140 | 0.210 |
Why?
| | Vagus Nerve Stimulation | 2 | 2019 | 24 | 0.210 |
Why?
| | Neurologists | 1 | 2021 | 19 | 0.200 |
Why?
| | Oligonucleotides, Antisense | 1 | 2021 | 100 | 0.200 |
Why?
| | Intellectual Disability | 1 | 2022 | 136 | 0.190 |
Why?
| | Infusions, Intraventricular | 1 | 2020 | 5 | 0.190 |
Why?
| | Neuronal Ceroid-Lipofuscinoses | 1 | 2020 | 3 | 0.190 |
Why?
| | Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2020 | 5 | 0.190 |
Why?
| | Aminopeptidases | 1 | 2020 | 12 | 0.190 |
Why?
| | Serine Proteases | 1 | 2020 | 15 | 0.190 |
Why?
| | Infusion Pumps | 1 | 2020 | 32 | 0.190 |
Why?
| | Drug Therapy, Combination | 1 | 2023 | 965 | 0.180 |
Why?
| | Leukoencephalopathies | 1 | 2020 | 32 | 0.180 |
Why?
| | Hemiplegia | 1 | 2019 | 19 | 0.180 |
Why?
| | Dystonic Disorders | 1 | 2019 | 17 | 0.180 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 4551 | 0.180 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2019 | 46 | 0.180 |
Why?
| | Electrocardiography | 1 | 2022 | 556 | 0.180 |
Why?
| | DNA Polymerase gamma | 1 | 2019 | 7 | 0.170 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2019 | 27 | 0.170 |
Why?
| | NAV1.1 Voltage-Gated Sodium Channel | 1 | 2019 | 15 | 0.170 |
Why?
| | Spasm | 3 | 2023 | 19 | 0.170 |
Why?
| | Neural Cell Adhesion Molecules | 1 | 2019 | 24 | 0.170 |
Why?
| | Speech Disorders | 1 | 2019 | 35 | 0.170 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 2019 | 35 | 0.170 |
Why?
| | Glucose Transporter Type 1 | 1 | 2019 | 42 | 0.170 |
Why?
| | Age of Onset | 2 | 2017 | 467 | 0.170 |
Why?
| | Neurosurgical Procedures | 1 | 2020 | 164 | 0.170 |
Why?
| | Delphi Technique | 1 | 2019 | 164 | 0.160 |
Why?
| | Pilot Projects | 1 | 2023 | 1418 | 0.160 |
Why?
| | Receptors, GABA-A | 1 | 2019 | 89 | 0.160 |
Why?
| | Preexisting Condition Coverage | 1 | 2017 | 2 | 0.160 |
Why?
| | Family | 1 | 2022 | 585 | 0.160 |
Why?
| | Retrospective Studies | 5 | 2023 | 12974 | 0.160 |
Why?
| | Family Health | 1 | 2019 | 201 | 0.160 |
Why?
| | Drug Resistant Epilepsy | 1 | 2018 | 48 | 0.150 |
Why?
| | Prednisolone | 1 | 2017 | 76 | 0.150 |
Why?
| | Cognition Disorders | 2 | 2019 | 529 | 0.150 |
Why?
| | Calcium-Binding Proteins | 1 | 2019 | 217 | 0.150 |
Why?
| | Sequence Analysis, DNA | 1 | 2020 | 755 | 0.150 |
Why?
| | Caregivers | 1 | 2023 | 709 | 0.150 |
Why?
| | Infant, Newborn | 3 | 2022 | 5255 | 0.150 |
Why?
| | Recombinant Proteins | 1 | 2020 | 1308 | 0.140 |
Why?
| | Genomics | 1 | 2021 | 706 | 0.140 |
Why?
| | Health Surveys | 1 | 2018 | 454 | 0.140 |
Why?
| | Patient Care Team | 1 | 2020 | 521 | 0.130 |
Why?
| | Psychometrics | 3 | 2024 | 631 | 0.130 |
Why?
| | Reproducibility of Results | 4 | 2024 | 2874 | 0.130 |
Why?
| | Nerve Tissue Proteins | 1 | 2019 | 551 | 0.130 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2014 | 19 | 0.130 |
Why?
| | Follow-Up Studies | 1 | 2023 | 4596 | 0.130 |
Why?
| | Nervous System Malformations | 1 | 2014 | 33 | 0.120 |
Why?
| | Disease Management | 1 | 2018 | 571 | 0.120 |
Why?
| | Parents | 1 | 2022 | 1212 | 0.120 |
Why?
| | Disease Progression | 1 | 2021 | 2490 | 0.120 |
Why?
| | Point Mutation | 1 | 2014 | 228 | 0.120 |
Why?
| | Prospective Studies | 3 | 2022 | 6471 | 0.110 |
Why?
| | Proteins | 1 | 2019 | 937 | 0.110 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1440 | 0.110 |
Why?
| | Disease Models, Animal | 2 | 2019 | 3730 | 0.110 |
Why?
| | Age Factors | 1 | 2019 | 2995 | 0.100 |
Why?
| | DNA-Binding Proteins | 1 | 2019 | 1346 | 0.100 |
Why?
| | Pediatrics | 1 | 2018 | 985 | 0.100 |
Why?
| | HEK293 Cells | 2 | 2019 | 625 | 0.070 |
Why?
| | Muscle Hypotonia | 1 | 2023 | 31 | 0.060 |
Why?
| | Failure to Thrive | 1 | 2023 | 31 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3174 | 0.060 |
Why?
| | Motor Skills | 1 | 2024 | 85 | 0.060 |
Why?
| | Suggestion | 1 | 2022 | 5 | 0.060 |
Why?
| | Munc18 Proteins | 1 | 2022 | 23 | 0.050 |
Why?
| | Chromosome Aberrations | 1 | 2022 | 136 | 0.050 |
Why?
| | Time-to-Treatment | 1 | 2023 | 148 | 0.050 |
Why?
| | Patient Acuity | 1 | 2021 | 37 | 0.050 |
Why?
| | Cerebral Palsy | 1 | 2022 | 80 | 0.050 |
Why?
| | Animals | 2 | 2019 | 33381 | 0.050 |
Why?
| | Data Interpretation, Statistical | 1 | 2022 | 336 | 0.050 |
Why?
| | Proteostasis Deficiencies | 1 | 2019 | 7 | 0.040 |
Why?
| | Unfolded Protein Response | 1 | 2019 | 46 | 0.040 |
Why?
| | Vitamin B 6 Deficiency | 1 | 2019 | 5 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 521 | 0.040 |
Why?
| | Vitamin B 6 | 1 | 2019 | 9 | 0.040 |
Why?
| | Pyridoxal Phosphate | 1 | 2019 | 21 | 0.040 |
Why?
| | Pyridoxine | 1 | 2019 | 26 | 0.040 |
Why?
| | Diet, Ketogenic | 1 | 2019 | 32 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2021 | 599 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2020 | 191 | 0.040 |
Why?
| | Corpus Callosum | 1 | 2019 | 57 | 0.040 |
Why?
| | Mutation, Missense | 1 | 2020 | 300 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2020 | 456 | 0.040 |
Why?
| | Consensus | 1 | 2020 | 534 | 0.040 |
Why?
| | White Matter | 1 | 2020 | 115 | 0.040 |
Why?
| | Protein Transport | 1 | 2019 | 412 | 0.040 |
Why?
| | Autism Spectrum Disorder | 1 | 2022 | 323 | 0.040 |
Why?
| | Emotions | 1 | 2022 | 495 | 0.040 |
Why?
| | Alternative Splicing | 1 | 2019 | 193 | 0.040 |
Why?
| | Down Syndrome | 1 | 2022 | 356 | 0.040 |
Why?
| | Gastrointestinal Diseases | 1 | 2019 | 187 | 0.040 |
Why?
| | Advisory Committees | 1 | 2018 | 212 | 0.040 |
Why?
| | Alleles | 1 | 2019 | 832 | 0.040 |
Why?
| | Protein Conformation | 1 | 2019 | 848 | 0.030 |
Why?
| | Genotype | 1 | 2020 | 1882 | 0.030 |
Why?
| | Zebrafish | 1 | 2019 | 434 | 0.030 |
Why?
| | Organ Size | 1 | 2014 | 460 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1435 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1795 | 0.020 |
Why?
| | Logistic Models | 1 | 2014 | 1900 | 0.020 |
Why?
| | Aged | 1 | 2022 | 19652 | 0.010 |
Why?
| | United States | 1 | 2020 | 12555 | 0.010 |
Why?
| | Middle Aged | 1 | 2019 | 27613 | 0.010 |
Why?
|
|
Demarest's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|